New Jersey’s bioscience industry is an innovative and growing component of the overall U.S. economy. With a track record of generating high-quality jobs and steady growth, the bioscience industry has been a consistent engine for our economy and a key strength during past economic recessions. American innovation in bioscience helps support state and local communities in a variety of ways ranging from job creation, construction, tax revenues, and other economic impact values.

Driven by small-company innovators, the bioscience industry has also mobilized in an unprecedented manner to address the global COVID-19 pandemic, while continuing to develop other life-saving and life-enhancing products and services for the U.S. and the world. America’s bioscience industry as an innovator and economic driver has never been more important, both for our health and our economic stability.

Total Number of Facilities in New Jersey 94
Jobs Directly Supported by the Industry in New Jersey 104989
Annual Average Wage
Total Clinical Trials
Dollar Amount Invested in Clinical Trials
$320.4 Million
Clinical Trial Participants
Total Clinical Trial Economic Impact
$879.7 Million

View Facilities By District

District Total Facilities in District View Facilities in District
NJ01 1 Ethicon Endo-Surgery, Inc (H)
NJ03 2 BioNJ (O)

UroGen Pharma, Inc. (H)

NJ05 3 BeiGene, Ltd. (H)

Eisai, Inc. (H)

PsychoGenics Inc. (H)

NJ06 10 BASF Corp (A)

Janssen Pharmaceutical Companies (H)


Johnson & Johnson (H)

Legend Biotech USA, Inc. (H)

PTC Therapeutics, Inc. (H)

Rutgers University Cell and DNA Repository (RUCDR) (O)

Rutgers University, Waksman Institute (O)

Rutgers, SUNJ – Human Genetics Institute (O)

Rutgers, The State University of New Jersey (O)

NJ07 31 Anima Biotech Inc. (H)

BASF Corp (A) (2)

Bellerophon Therapeutics (H)

Celgene Corporation (H)


Chugai Pharma USA (H)

Cyclacel Pharmaceuticals, Inc (H)

Drais Pharmaceuticals, Inc (H)


Insmed Inc. (H)

Ipsen Biopharmaceuticals, Inc. (H)

J&J Supply Chain & Supply Chain IT (O)

Janssen Diagnostics and Global Services, Inc. (H)

Janssen Global Services, LLC (H)

Janssen Oncology (H)

Janssen Reseach & Development, L.L.C. (H)

Janssen Therapeutics (H)

Jubilant Therapeutics, Inc. (H)

Mallinckrodt Pharmaceuticals (H) (2)

NPS Pharmaceuticals, Inc (H)

Ortho Clinical Diagnostics (H)

Polypid, Inc. (H)

Princeton Capital Advisors (O)

Recordati Rare Diseases (H)

Reliant Pharmaceuticals, Inc (H)

Sanofi (H) (2)

Signal Pharmaceuticals, Inc (H)

Tyme Technologies Inc. (H)

NJ08 1 Scynexis, Inc. (H)
NJ10 3 BASF Corp (A)

Merck (H)

Rutgers Business School, Biotech Commercialization Center (O)

NJ11 22 Allergan (H)

BASF Corporation (A)

Bayer Consumer Care (H)

Bayer HealthCare LLC (H)

Celgene Cellular Therapeutics (H)

Cellectar Biosciences, Inc. (H)



EluSys Therapeutics, Inc (H)

Elusys Therapeutics, Inc. (H)


Modern Meadow, Inc. (A)

Novartis Consumer Health, Inc. (H)

Novartis Oncology (H)

Novartis Pharmaceuticals Corporation (H) (3)

Organon & Co. (H)

Pfizer Consumer Group (H)

Pfizer Inc (H)

Shionogi Inc. (H)

The Medicines Company (H)

NJ12 21 Elucida Oncology, Inc (H)

Genmab (H)

Genmab, US Inc. (H)

Janssen Pharmaceutical Services (H)

Janssen Pharmaceuticals, Inc. (H)

Janssen Reseach & Development, L.L.C. (H)

Kayothera Inc. (H)

KBP Biosciences Co. Ltd. (H)

Medarex, Inc (H)

New Jersey Health Foundation (O)

Outlook Therapeutics, Inc. (H)

Palatin Technologies, Inc (H)

Pharmasset, Inc (H)

PMV Pharmaceuticals, Inc. (H)

Progenics Pharmaceuticals, Inc. (H)

Rafael Pharmaceuticals, Inc. (H)

Sandoz, Inc (H)

Shinkei Therapeutics (H)

Soligenix, Inc. (H)

TAXIS Pharmaceuticals, Inc. (H)

Transave, Inc (H)